Inogen, Inc. Provides Preliminary Unaudited Revenue Guidance for the Three-Month and Twelve-Month Periods Ended December 31, 2021
January 10, 2022 at 07:00 am
Share
Inogen, Inc. provided preliminary unaudited revenue guidance for the three-month and twelve-month periods ended December 31, 2021. For the three months, the company expects revenue to be in the range of $75.9 to $76.9 million, up 2.6% to 3.9% from the same period in 2020.
For the year, the company expects revenue to be in the range of $357.5 to $358.5 million, up 15.9% to 16.2% from 2020.
Inogen, Inc. is a medical technology company offering respiratory products for use in the homecare setting. The Company supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Its Inogen One systems reduces patients' reliance on stationary concentrators and oxygen compressed gas tanks. Its Inogen Connect is a wireless connectivity platform for the Inogen One G4, Inogen One G5 and Rove 6 consisting of a front-end mobile application for use by long-term oxygen therapy users and a back-end database portal for use by homecare providers. It also offers Simeox, which is an airway clearance device.
INOGEN, INC. 
